8-K filing — Phio Pharmaceuticals Corp. (PHIO)
Filed: 2026-10-13 AccNo: 0001437749-26-032505 Size: 182 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Phio Announced Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with a Buy and maintains $14 price target.
Phio Pharmaceuticals Receives US Notice Of Allowance For Patent Covering PH-894, Further Strengthening Company's IP Portfolio
PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio